SMS Pharmaceuticals Limited — Others, 12-02-2025: Monitoring Agency Report

SMS Pharmaceuticals Limited has disclosed its Monitoring Agency Report for the quarter ended December 31, 2024, regarding the utilization of proceeds from its recent preferential issue of convertible warrants, amounting to ₹114.30 crore. The report indicates there were no deviations from the disclosed uses of funds, as no funds were utilized in Q3 FY25, leaving ₹28.57 crore unutilized. This lack of fund deployment could lead to cautious sentiment among investors, as it highlights a slower pace in capital expenditure and operational ramp-up. The company plans to utilize the funds as objectives progress, maintaining a positive outlook for future potential utilization.